GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » PS Ratio

Homology Medicines (Homology Medicines) PS Ratio : 2.60 (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Homology Medicines's share price is $0.9347. Homology Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.36. Hence, Homology Medicines's PS Ratio for today is 2.60.

Good Sign:

Homology Medicines Inc stock PS Ratio (=2.6) is close to 10-year low of 2.6

The historical rank and industry rank for Homology Medicines's PS Ratio or its related term are showing as below:

FIXX' s PS Ratio Range Over the Past 10 Years
Min: 2.6   Med: 36.89   Max: 529.8
Current: 2.6

During the past 8 years, Homology Medicines's highest PS Ratio was 529.80. The lowest was 2.60. And the median was 36.89.

FIXX's PS Ratio is ranked better than
79.36% of 993 companies
in the Biotechnology industry
Industry Median: 9.09 vs FIXX: 2.60

Homology Medicines's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.36.

Warning Sign:

Homology Medicines Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Homology Medicines was -64.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -30.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -19.90% per year.

During the past 8 years, Homology Medicines's highest 3-Year average Revenue per Share Growth Rate was 48.80% per year. The lowest was -30.20% per year. And the median was 12.20% per year.

Back to Basics: PS Ratio


Homology Medicines PS Ratio Historical Data

The historical data trend for Homology Medicines's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines PS Ratio Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial 523.31 191.90 5.92 22.54 30.40

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.54 18.47 18.48 34.47 30.40

Competitive Comparison of Homology Medicines's PS Ratio

For the Biotechnology subindustry, Homology Medicines's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Homology Medicines's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's PS Ratio distribution charts can be found below:

* The bar in red indicates where Homology Medicines's PS Ratio falls into.



Homology Medicines PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Homology Medicines's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.9347/0.36
=2.60

Homology Medicines's Share Price of today is $0.9347.
Homology Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Homology Medicines  (NAS:FIXX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Homology Medicines PS Ratio Related Terms

Thank you for viewing the detailed overview of Homology Medicines's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (Homology Medicines) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Executives
Paul Alloway officer: See Remarks C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour officer: Chief Scientific Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum officer: Chief Commercial Officer C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith officer: CFO, Treasurer & Secretary C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos director, officer: President & CEO C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly officer: See Remarks C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn director, 10 percent owner, other: *Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty officer: Chief Operating Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109

Homology Medicines (Homology Medicines) Headlines

From GuruFocus